SCHEMBL16211583

SCHEMBL16211583

Fc1nc(N2CCC(F)(F)C2)c2nc[nH]c2n1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 18/20 0.43
GRM4 Q14833 1/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16211670 0.85 CNR2 (0.50) CNR2
SCHEMBL16211635 0.82 CNR2 (0.57) CNR2
SCHEMBL16212037 0.81 CNR2 (0.56) CNR2
SCHEMBL20171876 0.80 HTT (0.41)
SCHEMBL16211720 0.77 CNR2 (0.42) CNR2
SCHEMBL20093537 0.76 HRH4 (0.45) CNR2
SCHEMBL14183776 0.70 ABCB1 (0.46)
SCHEMBL16222478 0.67 CNR2 (0.58) CNR2
SCHEMBL16222603 0.65 CNR2 (0.42) CNR2
SCHEMBL2526551 0.65 PARP1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991987-B1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2018-05-23 EP disclosed
EP-2991987-B1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2018-05-23 EP disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
EP-2991987-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2016-03-09 EP disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
WO-2014177490-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed
WO-2014177490-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS CNR1, CNR2, P2RY1 CNR2 2/4885GRM4 321/4885JAK2 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.